Effective desensitization for a strong donor‐specific HLA antibody in a case of HLA‐mismatched allogeneic hematopoietic cell transplantation

We describe a unique ABO compatible and 9/10 HLA‐matched case of successful allogeneic hematopoietic cell transplantation (HCT) after effective desensitization of a strong anti‐HLA‐A24 donor‐specific antibody (DSA) with mean fluorescence intensity of approximately 18 000. Due to absence of a suitable matched unrelated donor the patient sibling was considered the best available donor, and it was decided to desensitize patient prior to transplant. The strength of HLA‐A24 DSA slowly decreased over the course of treatment, necessitating a total of 23 sessions of therapeutic plasma exchange in order to bring the DSA strength to undetectable levels, followed by a successful transplant. In summary, the outcome of this case shows effective application of desensitization treatment to remove strong DSA in HCT patients.

[1]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[2]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue , 2019, Journal of clinical apheresis.

[3]  N. Takahashi,et al.  Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor , 2019, Bone Marrow Transplantation.

[4]  J. Friedewald,et al.  Prognostic tools to assess candidacy for and efficacy of antibody‐removal therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  A. Ganser,et al.  Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.

[6]  H. Tanaka,et al.  Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation , 2017, Bone Marrow Transplantation.

[7]  N. Dunbar,et al.  Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition , 2016 .

[8]  P. Thall,et al.  Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  D. Gladstone,et al.  Donor HLA-specific Abs: to BMT or not to BMT? , 2015, Bone Marrow Transplantation.

[10]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[11]  T. A. Sivakumaran,et al.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. , 2013, Blood.

[12]  A. Zachary,et al.  Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  Brent R Logan,et al.  A perspective on the selection of unrelated donors and cord blood units for transplantation. , 2012, Blood.

[14]  H. Tamaki,et al.  Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT , 2012, Bone Marrow Transplantation.

[15]  P. Thall,et al.  Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. , 2011, Blood.

[16]  H. Azuma,et al.  The impact of anti-HLA antibodies on unrelated cord blood transplantations. , 2010, Blood.

[17]  P. Thall,et al.  High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation , 2009, Transplantation.

[18]  Loren Gragert,et al.  Estimation of HLA-A, -B, -DRB1 haplotype frequencies using mixed resolution data from a National Registry with selective retyping of volunteers. , 2007, Human immunology.

[19]  S. Chu,et al.  Effect of plasmapheresis for acute humoral rejection after heart transplantation. , 2006, Transplantation proceedings.

[20]  M. Pescovitz,et al.  Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. , 2004, Human immunology.

[21]  John P Klein,et al.  A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. , 2004, Blood.